High-grade B-cell lymphoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Loncastuximab tesirine monotherapy Variant #01 Partial | — | — | 21d | — | — | ~16 | — | — |
Axicabtagene ciloleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | 1 |
Epcoritamab monotherapy Variant #01 Partial | — | — | 28d | — | — | ~6 | — | — |
Tisagenlecleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Lisocabtagene maraleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
5 of 5 regimens shown